Gelest, Inc., headquartered in Morrisville, PA, USA, was founded in 1991 to serve the advanced technology applications markets and is recognized worldwide as an innovator, manufacturer and supplier of Organo-Silicon and Metal-Organic materials for commercial production and R&D support. Since its inception, Gelest, Inc. has continuously added experts in the fields of silanes, silicones, and metal-organics. The technical staff includes individuals with extensive hands-on experience and academic credentials (see Management Team). Joint developments between customers and staff have led to an increased product offering from several hundred materials to the current listing of several thousand materials. The company has focused its research and development efforts toward expanding the offering of Group 4A and 4B analogs. Gelest, Inc. offers the most comprehensive selection of silane, silicone, and metal-organic materials in the world

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

ResinTech Inc., an acknowledged leader in ion exchange, manufactures a broad range of ion exchange resins for water and waste water treatment, including deionization,softening, metals removal, product purification, resource recovery, and pollution control. In addition to its ion exchange resins, ResinTech supplies activated carbon and inorganic selective exchangers. ResinTech has developed an application technology resource group that includes state-of-the-art laboratories and a group of scientists dedicated to expanding the frontiers of application technology. This group is put to use whenever product or process recommendations are requested, assuring customers get the most cost-effective approach to achieving their process goals.

Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system. The melanocortin system is involved in regulating important physiological activities such as food intake and energy balance, desire and arousal, and the resolution of harmful inflammation. We are the first company to obtain FDA approval for a melanocortin based therapeutic, Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD). With the successful development of Vyleesi® and our extensive experience in the development of melanocortin based therapeutics, we are now focused on developing therapeutics that take advantage of the key role that the melanocortin system plays in the resolution of harmful inflammation. This has the potential to treat diseases that affect the eye, gastrointestinal system and the kidney. Our most advanced ocular product is PL9643, a topical treatment for dry eye disease, which is targeted to enter Phase 3 clinical trials in 2H 2021. We also have therapeutics in earlier stages of development for ophthalmic indications such as non-infectious uveitis, retinopathies and corneal diseases. Therapeutics that modulate the activity of the melanocortin system will have broad utility and to establish this, we are planning to conduct proof of concept clinical studies in ulcerative colitis and kidney disease. Vyleesi® is the first and only on-demand, FDA-approved treatment for premenopausal women suffering with HSDD, which affects 1 in 10 pre-menopausal women. Learn about this condition here: https://www.unblush.com/ To learn more about Vyleesi®, including Important Safety Information, visit here: https://www.vyleesi.com/ We are very excited by the tremendous potential our therapeutics have to positively impact the lives of patients and the value we can build for our shareholders. Find more information about our programs: www.palatin.com

Sigmapharm Laboratories, LLC, a privately held specialty pharmaceutical company, is engaged in the development, manufacturing and marketing of unique generic and branded products. Our company also provides contract development and manufacturing of patentable, stable and maximally bioavailable formulations of new chemical entities. Our products are developed and manufactured using our proprietary drug delivery systems which can effectively optimize drug solubility, bioavailability and stability. Presently, our company and its affiliates control more than seventy (70) formulation patents worldwide. In addition, we are fully integrated (sometimes referred to as ‘backward integrated’).

At Madison Industries, we understand our customers’ needs and expectations are constantly evolving. We’re committed to providing outstanding products and services to meet these ever changing needs. Madison sets the industry standard for functionality, architectural excellence, value, timeliness and safety, all with an excellent history of customer satisfaction. We are the premier modular building manufacturer. Modular buildings are shop assembled, including all mechanical systems and finishes. The intent is to transport the completed structure to the job site in sections, place it on foundations, complete the final electrical, mechanical and plumbing hook ups, and start operations within days of setting the building. Shop assembly decreases costs, improves product consistency and quality, and allows for construction to continue without delay during inclement weather. In addition, Madison buildings come in on budget with set contract pricing making the final cost predictable. Some typical uses for Madison's modular structures are convenience stores, car washes, restaurants, medical buildings and prisons. Consult your accountant for the possible income tax advantages of modular buildings.Madison Industries produces a complete line of metal products and structures from simple architectural elements to complete turnkey transportable buildings. Madison Industries continues to lead the industry by innovating and refining its products while keeping in mind that quality and service are always in demand.

Guardian Drug Company was founded in 1984 by Dr. Arvind Dhruv. Guardian is one of the nation's largest manufacturers of over-the-counter (OTC) pharmaceuticals. For 30 years, we have built a reputation for delivering the highest quality products, outstanding service and product innovation to the nation's leading drug store chains, mass merchandisers, supermarket chains, wholesalers and distributors. We ensure that every product meets or exceeds national brand quality which helps build customer loyalty, drives repeat sales, and enhances your business.

When the success of your clinical development program or drug product delivery is at stake, you can’t afford costly manufacturing delays. You deserve to work with a partner that puts your project — and you — first. It’s time to experience exceptional service. That’s the Experic difference. When you trust your project to Experic, you get a team of experts you can count on to deliver customized solutions that work for you. We specialize in advanced manufacturing, packaging and labeling technologies that accommodate a variety of dosing and packaging formats. With a 45,500-square-foot, state-of-the-art Class A research, manufacturing and packaging facility focused on powder filling and low-dose dry powder inhalation, we provide a hands-on, personalized approach to your development project that is backed by unparalleled industry experience and access to superior equipment solutions. Our approach is enhanced by our partnership with Harro Höfliger and use of its state-of-the-art filling equipment that offers extensive, cost-effective options for your program. • Powder blending and formulation development (inhalation (DPI) and oral solid) • Powder filling and low-dose powder filling technology • Precise filling capabilities with 100% high-speed check weighing • Encapsulation/over-encapsulation Find out more about our top-notch customer service and high-quality, on-time product delivery by visiting our website or emailing us at [email protected]. Experience It With Experic

Ardex formulates and produces an extensive array of professional automotive detailing products right here in the U.S.A. Drawing on decades of experience, we supply everything from the finest to some of the most economical products on the market today. Ardex Labs offers more than just chemical detailing products and accessories; we offer decades of experience in your industry to make your job easier, more efficient, and cost effective. Our sales and support staff will equip you with the knowledge to take on the toughest tasks ‐ whether you are a high volume auctionhouse or fleet‐operator, spot delivering a luxury sedan, or ceramic coating an exotic sports car, Ardex can help you focus on bringing new business ‐ rather than focusing on vendors.

United Chemical Technologies was founded in Horsham, PA in 1986. Since then, UCT has evolved into a major competitor in the field of silica-based solid phase extraction. In October 1993, UCT acquired the specialty chemical branch of Huls America (Petrarch). This expansion into silane manufacturing allows for greater control over the chemical processes involved in producing our high-quality bonded phases. At UCT, we are committed to creating the highest quality products and distinguishing ourselves by the service, from salesperson to technical support, that we provide to every customer. As our company has grown over the past three decades, our solid phase product offerings have expanded as well. Every product that UCT makes, from columns to well plates, QuEChERS, polymeric based SPE, derivatizing reagents, GC liners, and manifolds are manufactured to the highest standards. We now offer hydrolyzing enzymes and HPLC Columns, and we have developed products for the cannabis industry that include pesticide and purity testing. Our diverse product offerings, dedicated staff, and loyal customers have made UCT what it is today. Now, we focus on the future and another successful 30 years!

Pflaumer Brothers Inc is a chemicals company based out of 1008 Whitehead Rd Ext, Ewing Township, NJ 08638.

At PMC Biogenix, renewable resources are at the core of our development, manufacturing and marketing of specialty chemicals. For over 50 years, we have prioritized innovation and client-need in our chemical products portfolio. PMC Biogenix chemical products are found as the basis for many other applications in a broad range of industries, including consumer and household care, crop protection, polymers and plastics, wire and cable and many other markets. As a global pioneer in the research and development and ultimately the manufacture of oleochemical derivatives, we aim to deliver product applications in nearly every chemical end market. PMC Biogenix chemists are available to assist you in deciding which of our products meet your specific needs. We invite you to contact us for product literature or any additional information you may need.